Replies to post #508730 on Anavex Life Sciences Corp (AVXL)

[poguemahone]

Mayo:

Please do ask some hard questions. The CCs are a joke, with DM reading brief prepared remarks that often ignore pertinent updates on clinical programs and then “opening” the call to questions. What then follows is Soumit congratulating DM on “all the progress” and then asking some softball questions which provide minimal clarity to the company’s strategic plans.

After 10 years of attracting few new analysts, one would think DM would try a different approach to attract more interest in the company. I also dispute DM’s claim that the company has been transparent with shareholders. The one and only in-person interaction we could have this past year, the Annual Meeting, was relegated to a live-streaming event this year—very cowardly on Missling’s part.

I think DM has done an abysmal job as CEO, and am shocked the BOD has allowed him to remain in this capacity (nepotism at its finest). If this recent news from the EMA has highlighted anything, it is how detached our leadership is from the reality of getting a drug successfully through the approval process and to commercialization.

We need a major change in leadership—this ship is listing in heavy seas!

[AnavexBill]

Mayo, that is very good to hear. Currently, I think many shareholders have significant doubts about DM’s competence and possibly even if he can be trusted to tell shareholders the complete truth about everything that has transpired.

In summary, there is a big mess on Aisle 3 that needs to be cleaned up.

[oldmystic]

I plan to ask difficult questions

For instance?
with all due respect

[Graniteguy]

Also, with your plan in mind of asking more difficult questions, would you be able to share with the Anavex faithful, if you get significant pushback on particular questions before the session? I would be interested to know what is considered off limits or too controversial for the Anavex management team to publicly discuss.

[BakedLangostino]

thank you. will you also please ask about pricing -- I know it seems irrelevant now (this will date me but I am reminded by the famous Jim Mora "playoffs?!" interview line) but all financial models will change drastically if we do not win the appeal and shareholders deserve to know how the company plans to maximize revenue going forward to offset the damage from this rejection. Will they increase the price, or lower it to attract more customers? Or are they just going to take the loss financially? How do they plan to to market this so it can reach the greatest number of patients? Stuff like that but knowing an expected price -- if we can get out of this conference call with just that single piece of information, we can begin to accurately forcast impacts of potential dilution. Without pricing, it's all a guessing game and with enough pressure I think it would help for the public to hear on record just how much cheaper Blarcamesine really is. When the wolves begin howling, the EMA and FDA will listen.

I'm sure you will focus a lot on trial design, the appeals process, and all of that is important -- but this is probably the best opportunity to get some answers from Chris, or at least get him on record, regarding what the plan would have been had CHMP recommended approval last week.

Thanks as always, for your posts here and your service.

- Baked L.

[attilathehunt]

I plan to ask difficult questions as the shareholders should know what has been going on and what strategies are being pursued.

Don't settle for obscure answers!! Press HARD for factual answers.